Inventor · disambiguated record
Stefanie Urlinger
Also filed as: URLINGER STEFANIE
17 granted patents·15 pending applications·151 citations·filing 2003–2024
93Inventor score
Top patents by PatentIndex Score
32 records- 0191US10899841B2Anti-BAFFR antibody formulations and methods of use thereofNOVARTIS AG·Filed 2019·Granted Jan 26, 2021·3 cites·10 claims
- 0291US8388968B2Compositions and methods for increasing muscle growthBERGER CATRIN·Filed 2010·Granted Mar 5, 2013·66 cites·34 claims
- 0390US8106163B2Compositions and methods of use for therapeutic antibodiesHEUSSER CHRISTOPH·Filed 2009·Granted Jan 31, 2012·18 cites·13 claims
- 0489US9458240B2Anti-BAFFR antibody formulationsCOSENZA MARTA·Filed 2011·Granted Oct 4, 2016·8 cites·16 claims
- 0589US7541446B2Tet repressor-based transcriptional regulatory proteinsTET SYSTEMS HOLDING GMBH & CO·Filed 2003·Granted Jun 2, 2009·31 cites·13 claims
- 0687US2025163170A1Antibody formulationNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0784US2024425602A1Compositions and methods for increasing muscle growthNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0884US2025034270A1Compositions and methods of use for therapeutic antibodiesNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0983US8728981B2Collection and methods for its useURLINGER STEFANIE·Filed 2011·Granted May 20, 2014·8 cites·44 claims
- 1082US11254734B2Fab molecules with a rodent hinge region and a non-rodent CH1 regionMORPHOSYS AG·Filed 2017·Granted Feb 22, 2022·2 cites·7 claims
- 1181US9340620B2Compositions and methods of use for therapeutic antibodiesHEUSSER CHRISTOPH·Filed 2011·Granted May 17, 2016·5 cites·5 claims
- 1279US9541559B2Collection and methods for its useMORPHOSYS AG·Filed 2014·Granted Jan 10, 2017·2 cites·32 claims
- 1377US8367586B2Collection and methods for its useMORPHOSYS AG·Filed 2011·Granted Feb 5, 2013·2 cites·30 claims
- 1475US12054555B2Anti-BAFFR antibody formulations and methods of use thereofNOVARTIS AG·Filed 2020·Granted Aug 6, 2024·0 cites·10 claims
- 1575US9624293B2Collection and methods for its useMORPHOSYS AG·Filed 2014·Granted Apr 18, 2017·1 cites·14 claims
- 1674US9382326B2Compositions and methods of use for therapeutic antibodiesHEUSSER CHRISTOPH·Filed 2011·Granted Jul 5, 2016·2 cites·10 claims
- 1772US2022298251A1Compositions and methods of use for therapeutic antibodiesNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1869US2018179290A1Antibody formulationNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1968US8673306B2Compositions and methods of use for antibodies of dickkopf-1SHULOK JANINE·Filed 2007·Granted Mar 18, 2014·2 cites·11 claims
- 2064US2022135660A1FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 RegionMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 2163US2016368999A1Antibody formulationCOSENZA MARTA·Filed 2016·Application pending·0 cites
- 2262US9296813B2Compositions and methods of use for antibodies of Dickkopf-1SHULOK JANINE R·Filed 2014·Granted Mar 29, 2016·1 cites·19 claims
- 2360US2019135931A1Compositions and methods of use for therapeutic antibodiesNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2458US10647757B2Collection and methods for its useMORPHOSYS AG·Filed 2017·Granted May 12, 2020·0 cites·8 claims
- 2552US2016347851A1Compositions and methods of use for therapeutic antibodiesHEUSSER CHRISTOPH·Filed 2016·Application pending·0 cites
- 2652US2025326818A1Discernible cell surface protein variants for use in cell therapyUNIV BASEL·Filed 2022·Application pending·0 cites
- 2750US2025057951A1Discernible cell surface protein variants of cd117 for use in cell therapyUNIV BASEL·Filed 2022·Application pending·0 cites
- 2847US2014341901A1Compositions and methods of use for antibodies of dickkopf-1SHULOK JANINE R·Filed 2014·Application pending·0 cites
- 2945US2024010720A1Antibodies binding igv of igsf11 (vsig3) and uses thereofIOMX THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 3044US8273688B2Collection of HCDR3 regions and uses thereforENZELBERGER MARKUS·Filed 2006·Granted Sep 25, 2012·0 cites·7 claims
- 3140US2022372138A1Antibodies binding igc2 of igsf11 (vsig3) and uses thereofIOMX THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 3232US2021061908A1Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stefanie Urlinger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →